在人均寿命达到 100 岁的时代，艾塞瑞酮是否会被定位为任何年龄段人群的二线治疗药物？

{"title":"在人均寿命达到 100 岁的时代，艾塞瑞酮是否会被定位为任何年龄段人群的二线治疗药物？","authors":"Tetsuro Yoshida","doi":"10.1038/s41440-025-02133-y","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":13029,"journal":{"name":"Hypertension Research","volume":"48 4","pages":"1624-1626"},"PeriodicalIF":4.3000,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.com/articles/s41440-025-02133-y.pdf","citationCount":"0","resultStr":"{\"title\":\"In the era of 100-year life spans, will esaxerenone be positioned as a second-line treatment for any age group?\",\"authors\":\"Tetsuro Yoshida\",\"doi\":\"10.1038/s41440-025-02133-y\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":13029,\"journal\":{\"name\":\"Hypertension Research\",\"volume\":\"48 4\",\"pages\":\"1624-1626\"},\"PeriodicalIF\":4.3000,\"publicationDate\":\"2025-03-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.nature.com/articles/s41440-025-02133-y.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Hypertension Research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.nature.com/articles/s41440-025-02133-y\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"PERIPHERAL VASCULAR DISEASE\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hypertension Research","FirstCategoryId":"3","ListUrlMain":"https://www.nature.com/articles/s41440-025-02133-y","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}